Health
Anti-SARS-CoV-2 drug candidate enters phase I clinical trial – News-Medical.Net
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of…
DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.
Researchers found that DC402234 exhibits effective inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 0.053 ± 0.005 μM,…
-
Noosa News22 hours agoBrisbane man charged with arson and attempted murder after violent house fire at Wynnum West
-
Noosa News22 hours agoAI a ‘strategic necessity’ law lecturer says – Proctor
-
Noosa News23 hours agoEight International Travel Tips To Keep In Mind When Planning
-
Business19 hours agoDown 53% in a year, are Domino’s shares now on sale?